AdAlta Pipeline


We are utilising the power of our i-body technology platform to develop a pipeline of i-bodies (potential drugs), with an initial focus on treating fibrotic diseases.

Our lead i-body drug candidate AD-114 has anti-fibrotic effects in treating a type of fibrosis of the lung, known as idiopathic pulmonary fibrosis (IPF), and this is the indication that we are initially focusing on. AD-114 has also demonstrated anti-fibrotic effects in treating fibrosis of the eye and we are pursuing this as an additional indication.

We are also interested in broadening the application of AD-114 to other fibrosis indications, including demonstrating therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart.

AD-114 has key advantages for IPF treatment. These include:

  • specificity for diseased human tissue with effects only shown on IPF tissue and no effects displayed on normal lung tissue nor any evidence of off target effects;
  • more effective than existing IPF approved drugs showing greater in vitro efficacy compared to the only approved therapies Nintedanib and Pirfenidone;
  • demonstration in multiple animal models showing that AD-114 has both anti-fibrotic and anti-inflammatory effects; and
  • novel mechanism of action for fibrosis enabling a “first in class” therapy

AD-114 – idiopathic pulmonary fibrosis (IPF)

IPF is a highly lethal and rare disease with current treatment options only demonstrating a reduction in disease progression.

AD-114 has completed extensive pre-clinical studies with positive in vitro (in the lab) and in vivo (in animals) data obtained. For example, in animal lung mouse disease models treated with AD-114, collagen content and inflammatory cell infiltration is reduced thereby demonstrating a similar architecture to that of the normal lung.

AdAlta Pipeline

Normal
lung tissue

AdAlta Pipeline

IPF lung tissue
(lung disease mouse model)

AdAlta Pipeline

IPF lung tissue + AD-114
dosed for 21 days

(lung disease mouse model)


AD-114 – Eye

We have shown that the AD-114 i-body drug candidate, has anti-fibrotic effects in the eye.

We have been awarded a National Health and Medical Research (NHMRC) Development Grant, from the Australian Government, in collaboration with The University of Melbourne, The Centre for Eye Research Australia, Monash University and La Trobe University to assess the i-body AD-114 drug candidate for treatment in a number of fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication.

A successful outcome from this program will trigger the potential to progress development of the lead i-body drug candidate AD-114 in a second important area of clinical need.